Below are the 2 most recent journal entries recorded in arimaspi66's InsaneJournal:

Wednesday, December 7th, 2011
3:54 am	Buy buspar - minize or forget anxiety BuSpar and it is anxiolytic properties BuSpar is usually a psychoactive medication and it is mainly employed in management of generalized panic disorder (GAD) of mild to moderate intensity. However, it's not at all effective against panic and anxiety attacks, nor could it be efficient for treating ocd and social phobia. However, for generalized anxiety disorder, there are few other medications comparable to BuSpar. GAD is undoubtedly an anxiety disorder involving excessive and irrational be worried about everyday situations and things that is disproportionate to your real types of worries. There are numerous the signs of GAD, which include fatigue, headaches, numbness, muscle tension, difficulties swallowing, trembling, fidgeting, nausea, difficulties breathing and concentrating, agitation, sweating, insomnia and restlessness. However, Gad should not be confused with anxiety that a majority of in the population experiences in certain situations. It will be important for the aforementioned symptoms to be present and consistent for longer than six months to enable GAD to become diagnosed. BuSpar inhibits the receptors of serotonin from reuptaking serotonin, thus improving the amounts of these neurotransmitters, which ends up in the relief of hysteria symptoms. BuSpar doubles along with SSRI drugs in therapy created to treat depression. Another potential use, that also has to be tried and researched, includes improvements of memory and spatial learning after traumatic trouble for as their pharmicudical counterpart. These effects happen to be affecting trials on rodents, although human putting on BuSpar when this happens has to be tested. BuSpar is certainly caused by weighed against benzodiazepines because they're the course of medicine which can be most commonly found in treating anxiety conditions. V is superior to benzodiazepines because it doesn't show any likelihood of dependence and addiction, unlike benzodiazepines which are highly addictive. Also, prolonged by using v isn't going to cause tolerance just as the benzodiazepines which become tolerated to such extent over time that they become inefficient. However, BuSpar takes added time to demonstrate each of the benefits which is the reason why individuals who have been using benzodiazepines often find BuSpar being less effective buy wellbutrin without a prescription. In truth, when switching from benzodiazepines to BuSpar, it's advised the benzodiazepine treatment be gradually discontinued while introducing BuSpar, concerning avoid any withdrawal effects which might be common when discontinuing using benzodiazepines too suddenly. About BuSpar treatment There is often a volume of medical ailments which can be vulnerable to being exacerbated or affected by the BuSpar treatment and in addition they include liver and kidney diseases, closed-angle glaucoma, asthma along with obstructive airways diseases, epilepsy, certain heart problems, diabetes and myasthenia gravis. You need to on no account take v should you have taken any MAO inhibitors within a couple weeks from taking BuSpar. It's the same for the vice-versa case. The reality is that these medications can interact so that the outcome could even be lethal. It could be recommended that you inform yourself in-depth about every other interactions to medications, also about any side effects that could be a result of BuSpar. Your physician may be the only supply of information. . Current Mood: indescribable (Comment on this)
3:35 am	New study examines seroquel treatment for depressive episodes associated with bipolar disorder In the First Large-Scale SEROQUEL Study Including Both Bipolar I and Bipolar II Disorders, Approximately 50% of Patients Taking SEROQUEL Achieved Remission from Bipolar Depression Symptoms by Week 2 WILMINGTON, Del. , May 5 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results from the first large-scale study that examined SEROQUEL(R) (quetiapine fumarate) as a treatment for depressive episodes that included both patients with bipolar I and II disorders. Results from this clinical trial suggest improvement in depressive symptoms for those taking SEROQUEL. Depressive episodes are characterized by prolonged periods of sadness, unexplained loss of energy, persistent lethargy and recurring thoughts of death or suicide. SEROQUEL is a psychotropic medication approved for the short-term treatment of acute manic episodes associated with bipolar I disorder and the treatment of schizophrenia. This double-blind, placebo-controlled trial indicated that patients taking SEROQUEL had greater improvements in mean MADRS (Montgomery-Asberg Depression Rating Scale) scores than patients taking placebo (SQL 300mg= -16. 7 and SQL 600mg= -16. 4 vs. placebo -10. 3). These results were seen as early as week one and continued through week 8. After two weeks, approximately 50% of patients taking SEROQUEL achieved both a response* and remission** vs. placebo (p< 0. 001). "This study is unique because it is the first to examine SEROQUEL as a treatment for depressive episodes that included both patients with bipolar I and bipolar II disorders. These results are an important contribution to the scientific community," said Joseph Calabrese, MD, Co-Director of the National Institute of Mental Health Bipolar Research Center at University Hospitals of Cleveland and Case Western Reserve University. "Based on these exciting results, SEROQUEL should be further explored in the area of depressive episodes associated with bipolar disorder. " This study of 542 patients who were randomized to receive 8 weeks of treatment with fixed doses of SEROQUEL (300 mg, 600 mg) or placebo, administered once-daily, also evaluated anxiety symptoms. Results suggest improvement in anxiety symptoms at both doses from Day 8 (p10% and at least twice the placebo rate) were dry mouth, sedation, somnolence, dizziness and constipation; the tolerability profile is comparable to that seen in mania trials. IMPORTANT SAFETY INFORMATION Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL. SEROQUEL is indicated for the treatment of schizophrenia and the short-term treatment of acute manic episodes associated with bipolar I disorder. The physician who elects to use SEROQUEL for extended periods of time should periodically re-evaluate the long-term usefulness of the drug for individual patients. There have been reports of diabetes mellitus and hyperglycemia-related adverse events associated with the use of atypical antipsychotics, including SEROQUEL. The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, SGPT increase, dyspepsia and weight gain. For full prescribing information for SEROQUEL, please visit the website http://www. seroquel. com. ABOUT BIPOLAR DISORDER Bipolar disorder, which affects about 2. buy desyrel online 3 million American adults every year, consists of recurring episodes of mania and depression. Without appropriate treatment, patients with this disorder usually suffer for a lifetime with periods of wellness and functioning punctuated by severe episodes of illness. Both men and women are equally at risk for this illness, which most often emerges in adolescence or young adulthood and recurs throughout life. ABOUT ASTRAZENECA AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $18. 8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. In the United States, AstraZeneca is an $8. 7 billion healthcare business with more than 11,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit: http://www. astrazeneca-us. com. * Response rate defined as at least 50% decrease in MADRS from baseline ** Remission defined as MADRS total score <12. Current Mood: morose (Comment on this)